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Abstract
Metastatic colorectal cancer (mCRC) is still one of the 
tumor types with the highest incidence and mortal-
ity. In 2012, colorectal cancer was the second most 
prevalence cancer among males (9%) and the third 
among females (8%). In this disease, early diagnosis 
is important to improve treatment outcomes. However, 
at the time of diagnosis, about one quarter of patients 
already have metastases, and overall survival of these 
patients at 5-years survival is very low. Because of 
these poor statistics, the development of new drugs 
against specific targets, including the pathway of an-
giogenesis, has witnessed a remarkable increase. So, 
targets therapies through epidermal growth factor 
and its receptor and also KRAS pathways modulation 
acquired a main role whether in association with stan-
dard chemotherapy and radiotherapy. With the current 
knowledge in the field of molecular biology, including 
genetic mutations and polymorphisms, we know better 
why patients respond so differently to the same treat-
ments. So, in the future we can develop increasingly 
personalized treatments to the patient and not the dis-
ease. This review aims to summarize some molecular 
pathways and their relation to tumor growth, as well 
as novel targeted developing drugs and recently ap-
proved for mCRC.
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Core tip: Metastatic colorectal cancer (mCRC) treat-
ment remains a challenge for clinicians worldwide. Re-
cently, tumor molecular profile and tailored therapies 
are objects of great interest throughout the scientific 
community. Our manuscript will give the readers an 
interesting overview regarding the innovative drugs 
developing and recently approved for the treatment of 
mCRC.
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INTRODUCTION
Colorectal cancer (CRC) has high incidence and mortality 
worldwide. In 2012, CRC was the second most preva-
lent cancer type among males (9%) and the third among 
females (8%)[1]. Approximately 15%-25% of  patients 
with CRC present with synchronous liver metastases, and 
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v20.i30.10425
World J Gastroenterol  2014 August 14; 20(30): 10425-10431
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2014 Baishideng Publishing Group Inc. All rights reserved.
Personalizing medicine for metastatic colorectal cancer: 
Current developments
Andrea Marin Marques, Alice Turner, Ramon Andrade de Mello
10425 August 14, 2014|Volume 20|Issue 30|WJG|www.wjgnet.com
Marques AM et al . Targeted therapies and mCRC
80%-90% of  these have unresectable metastatic liver dis-
ease[2,3]. In addition to this, nearly 50% of  patients who 
are initially diagnosed with localized disease ultimately 
develop metastases[4]. Despite recent advances in the 
treatment of  advanced disease, the 5-year survival rates 
for patients with advanced CRC remain low[5]. Nowadays, 
in combination with standard therapy, two therapeutic 
strategies have demonstrated activity in metastatic CRC 
(mCRC) targeting the epidermal growth factor receptor 
(EGFR) and vascular endothelial growth factor (VEGF) 
both in first and second-line therapy[6,7]. Therefore, with 
developed in the knowledge and understanding of  mo-
lecular pathways was possible to the identification of  
genetic markers existed in some patients. This can be 
used as a therapeutic target or may to explain why some 
patients do not respond to target therapy. For example, 
tumors that have a mutation in codon 12 or 13 of  the 
KRAS gene are not sensitive to EGFR inhibitors. There 
is also some evidence that mutation in the BRAF gene 
conferring resistance to anti-EGFR therapy in the non-
first-line setting of  metastatic disease[8]. Thus, the role 
of  molecular biology in the characterization of  tumor is 
object of  great interest in order to improve the systemic 
treatment for mCRC. This review will focus briefly on 
novel issues related to personalizing medicine for mCRC.
ANGIOGENESIS PATHWAYS
Angiogenesis is a complex process mediated by a num-
ber of  intersecting pathways, including VEGF, angio-
poietins, notch, and integrins (Figure 1). In normal 
tissues, there is a balance between proangiogenic and 
antiangiogenic factors[9]. The VEGF family comprises 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placen-
tal growth factor (PlGF), 3 receptors [VEGF receptor 
(VEGFR)-1 (FLT-1), VEGFR-2 (FLK-1/KDR), and 
VEGFR-3 (FLT-4)], and 2 co-receptors [neuropilin 
(NRP)-1 and NRP-2]. VEGF-A binding to VEGF re-
ceptor (VEGFR)-2 is believed to be the key signaling 
pathway mediating angiogenesis[10]; by the increase of  
endothelial proliferation and survival it promotes endo-
thelial cell migration, increases vascular permeability, and 
alters gene expression. Tyrosine kinases are receptors for 
VEGF ligands and they are found primarily on vascular 
endothelial cells[11].
Tumor angiogenesis has peculiarities relating to the 
same process in healthy tissue. The endothelial layer 
is irregular and contains spaces that contribute to the 
extravasation of  particles as large as 2 μm from tumor 
vessels[12], proliferating tumor cells cause compression 
of  vessels[13], and interstitial pressure is increased. This 
causes an inadequate delivery of  therapeutic agents such 
as monoclonal antibodies[14]. The ability of  tumor ves-
sels to supply oxygen and remove waste products is thus 
compromised, resulting in hypoxia and acidosis in the 
tumor microenvironment. This further lowers the ef-
fectiveness of  anti-tumor treatments such as radiation 
therapy and chemotherapy[15].
CHEMOTHERAPY FOR ADVANCED OR 
mCRC
Relative to the standard chemotherapy for advanced or 
mCRC; the guidelines advocate the use of  the following 
schemes in initial therapy: fluorouracil, leucovorin, and ox-
aliplatin-based chemotherapy (FOLFOX), fluorouracil, leu-
covorin, and irinotecan-based chemotherapy (FOLFIRI)[16], 
capecitabine plus oxaliplatin (CapeOx or XELOX)[17] and 
fluorouracil, leucovorin, oxaliplatin and irinotecan-based 
chemotherapy (FOLFOXIRI)[18]. These drugs have been 
used since the 90’s for providing an improvement in the 
overall survival (OS) for metastatic patients[19].
In chemotherapy for advanced and mCRC, the addi-
tion of  a biologic agent is also advocated. The biologics 
agents for CRC include an anti-VEGF (bevacizumab)[20] 
or an anti-EGFR (cetuximab or panitumumab) for KRAS 
wild-type (WT) gene patients. They are recommended or 
listed as an option in combination with some of  the regi-
mens above. The OS was not found to be associated with 
the order in which these drugs were received. After the 
first progression of  the disease, the therapeutic regimen 
used should be changed, but some studies have demon-
strated the benefit of  continuing angiogenic suppression 
after first-progression following bevacizumab-containing 
cytotoxic regimen[21] though no benefit was observed 
with the use of  bevacizumab in the adjuvant setting.
ANTI-EGFR THERAPY
In mCRC, the anti-EGFR therapy that can be used is 
cetuximab and panitumumab. These are monoclonal 
antibodies that can be administered as monotherapy for 
patients with the KRAS wild type, or in association with 
standard chemotherapy[22]. Cetuximab was approved 
with 5-FU, leucovorin and irinotecan (FOLFIRI) for 
first-line therapy[23], on the other hand panitumumab was 
approved for use as monotherapy.
10426 August 14, 2014|Volume 20|Issue 30|WJG|www.wjgnet.com
Figure 1  Exemplification of bevacizumab mechanisms of action, which 
acts by inhibiting the vascular endothelial growth factor family ligands 
to their receptors and thus blocking tumor angiogenesis. VEGF: Vascular 
endothelial growth factor; PlGF: Placental growth factor.
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ANTI-VEGF THERAPY
In the class of  Anti-VEGF therapy, bevacizumab and 
aflibercept are currently interesting options. Bevacizumab 
is a recombinant humanized monoclonal IgG1 antibody 
that binds to and inhibits the biologic activity of  VEGF 
by preventing its binding to VEGFR-1 and VEGFR-2 
on the surface of  endothelial cells. The result is inhibi-
tion of  endothelial cell proliferation and new blood ves-
sel formation[24-26]. Aflibercept (VEGF Trap, known in 
the United States as ziv-aflibercept), is a recombinant 
fusion protein with receptor components of  VEGFR-1 
and VEGFR-2 that binds multiple ligands in the angio-
genesis network (VEGF-A, VEGF-B, and PlGF). It was 
demonstrated that this targeted therapy improved the 
survival of  mCRC patients as second-line treatment in 
combination with the FOLFIRI regimen in patients who 
had disease progression during first-line oxaliplatin-based 
chemotherapy[27,28]. Despite the demonstrated effective-
ness in progression-free-survival (PFS) and OS with the 
use of  bevacizumab in combination with common cyto-
toxic chemotherapies[7], there are some mechanisms of  
resistance to VEGF targeting[29]. In this framework, some 
hypotheses have been raised, such as the VEGF axis re-
lated resistance, the role of  non-VEGF modulators of  
angiogenesis in resistance, and the significance of  the 
stroma in the response to angiogenesis targeting[30].
CLINICAL DATA
At the current time, there are 8 new anti-angiogenic agents 
in trials and a new molecule approved by Food and Drug 
Administration (FDA) and European Medicine Agency 
(EMA)[31]. We will summarize below some important as-
pects regarding the main drugs in this field (Table 1).
Aflibercept
First, aflibercept, a fully humanized recombinant fusion 
protein that is composed of  domain 2 of  VEGFR-1 and 
domain 3 of  VEGFR-2 with the Fc fragment of  IgG1[32] 
as mentioned above. The phase Ⅲ VELOUR trial deter-
mined that patients receiving aflibercept with irinotecan/
5-FU as second line chemotherapy for mCRC experi-
enced increased time of  outcomes: median PFS for the 
aflibercept plus FOLFIRI arm was 6.90 mo vs 4.67 mo 
for the placebo-plus-FOLFIRI arm; and median OS for 
the aflibercept-plus-FOLFIRI arm was 13.50 mo vs 12.06 
mo for the placebo plus FOLFIRI arm. In this study, 
1226 patients were randomized to receive FOLFIRI plus 
placebo or aflibercept. However, toxicity (grade 3 or 4 of  
adverse events) were more common with the addition of  
aflibercept (n = 614) than in placebo (n = 612); also, near-
ly 1/3 of  these patients had previously been treated with 
bevacizumab[33]. The most common adverse events were: 
fatigue (63.8%), nausea (36.2%) and vomiting (27.7%), 
while the most common toxicities included dysphonia 
(46.8%), hypertension (38.3%) and proteinuria (10.6%)[34].
Sunitinib
Sunitinib is a small-molecule inhibitor of  the VEGF path-
way. It is a multi-targeted receptor tyrosine kinase inhibi-
tor (TKI), with both direct anti-proliferative effects and 
anti-angiogenic properties, targeting the VEGFR-2 as well 
as PDGFR-b, c-Kit and Ret[35]. However a recent study 
showed that sunitinib plus FOLFIRI was not superior to 
FOLFIRI alone and has a poorer safety profile in treat-
ment of  mCRC patients[36].
Vatalanib
Another biological agent is vatalanib, a TKI that blocks 
the activity of  VEGFR-1, VEGFR-2 and VEGFR-3. It 
also inhibits other class Ⅲ kinases, such as the platelet-
derived growth factor (PDGF) receptor beta tyrosine 
kinase, c-Kit, and c-Fms, but at higher concentrations[37]. 
Phase Ⅰ/Ⅱ studies have shown good results, but the 
data from a phase Ⅲ study, CONFIRM-1, showed that 
the addition of  vatalanib to FOLFOX-4 did not improve 
PFS. This was compared with FOLFOX-4 alone in pa-
tients with mCRC in first line treatment[38]. Nevertheless, 
the CONFIRM-2[39], which evaluated the same therapy 
as second line, showed that in patients with high levels 
of  lactate dehydrogenase, vatalanib could be useful[40].
Semaxanib
Semaxanib is an inhibitor of  VEGFR-1 and 2 tyrosine 
kinases that was shown to inhibit VEGF-dependent mi-
togenesis of  human endothelial cells without inhibiting 
the growth of  a variety of  tumor cells in vitro[41]. How-
ever, the results in phase Ⅲ trials did not show any im-
provement in clinical outcome with semaxanib in com-
bination with irinotecan vs fluorouracil irinotecan alone, 
as therapy for advanced CRC patients that had failed at 
least one prior treatment[42]. As well as this, severe toxic-
ity was observed.
Regorafenib
Regorafenib is a TKI against various pro-angiogenic and 
pro-proliferation targets[43]. It is the first anti-angiogenic 
molecule with survival benefits in mCRC which has pro-
gressed after all standard therapies[44]. In the CORRECT 
phase Ⅲ trial, it was randomized for 753 patients to 
initiate treatment (regorafenib n = 500; placebo n = 253; 
population for safety analyses). Median OS, the primary 
end-point, was 6.4 mo in the regorafenib group vs 5.0 
mo in the placebo group (HR = 0.77; 95%CI: 0.64-0.94; 
one-sided P = 0.0052). Treatment-related adverse events 
occurred in 465 (93%) patients assigned regorafenib and 
in 154 (61%) of  those assigned placebo. The most com-
mon adverse events of  grade three or higher related to 
regorafenib were hand-foot skin reaction (83 patients, 
17%), fatigue (48.10%), diarrhea (36.7%), hypertension 
(36.7%), and rash or desquamation (29.6%). These re-
sults were interesting, particularly, for the patients with 
KRAS mutant mCRC.
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Table 1  Summary of the main clinical trials regarding anti-angiogenic therapies
Brivanib
Another molecule being studied is brivanib, a TKI that 
specifically inhibits the VEGR-2 and FGFR-1 signal-
ing[45]. Some studies have been showed that brivanib can 
be used to restore the antiangiogenic activity in bevaci-
zumab-resistant patients[46]. A recent phase Ⅲ trial that 
compared the use of  brivanib and cetuximab with or 
without chemotherapy, demonstrated that despite posi-
tive effects on PFS and objective response, cetuximab 
plus brivanib increased toxicity and did not significantly 
improve OS in patients with metastatic, chemotherapy-
refractory, wild-type K-RAS colorectal cancer[47]. Taking 
this in account, more data are needed to clarify this issue.
Cediranib
Cediranib, a VEGFR tyrosine kinase inhibitor (VEGFR 
TKI), was tested in the HORIZON Ⅲ trial[48] in which 
cediranib plus FOLFOX6 was compared with bevaci-
zumab plus FOLFOX6 in patients with untreated mCRC. 
The results did not show significant differences in the 
10428 August 14, 2014|Volume 20|Issue 30|WJG|www.wjgnet.com
Drugs Ref. Trial Summary of the study Results (PFS; OS) Toxicity (grade 3 or 4 adverse 
events)
Aflibercept [33] VELOUR 
trial 
aflibercept with irinotecan/5-FU/
LV as second line chemotherapy 
for mCRC
Median PFS for the aflibercept plus 
FOLFIRI arm was 6.90 mo vs 4.67 mo for 
the placebo-plus-FOLFIRI arm
Grade 3 or 4 adverse events were 
more common with the addition 
of aflibercept (n = 614) or placebo 
(n = 612), nearly 1/3 of these pa-
tients had previously been treated 
with bevacizumab
Median OS for the aflibercept-plus-
FOLFIRI arm was 13.50 mo vs 12.06 mo 
for the placebo plus FOLFIRI arm
Sunitinib [36] Carrat et al[36] Double-blinded, phase Ⅲ study 
participants were randomly as-
signed to sunitinib plus FOLFIRI 
or placebo plus FOLFIRI
Median PFS for the sunitinib arm was 
7.8 mo (95%CI: 7.1-8.4 mo) vs 8.4 mo 
(95%CI: 7.6-9.2 mo) for the placebo arm
Diarrhea, stomatitis/oral 
syndromes, fatigue, hand-foot 
syndrome, neutropenia, throm-
bocytopenia, anemia, and febrile 
neutropenia)
Vatalanib [38-40] CON-
FIRM-1/
CONFIRM-2
These are multinational, random-
ized, double-blinded, phase Ⅲ 
studies. Patients were randomly 
assigned to receive vatalanib plus 
FOLFOX4 or placebo plus FOLF-
OX4 in 1ª or 2º line respectively for 
CONFIRM-1 or CONFIRM-2
Vatalanib and placebo, respectively, 
presented median OS was 13.1 and 11.9 
mo (HR = 1.00; 95%CI: 0.87-1.16; P = 
0.957). Median PFS was with placebo 
(5.6 and 4.2 mo, respectively; HR = 0.83; 
95%CI: 0.71-0.96; P = 0.013). An explor-
atory, post hoc analysis demonstrated 
improved PFS in patients with high 
LDH, regardless of WHO PS (HR = 0.63; 
95%CI: 0.48-0.83; P < 0.001)
The incidence of grade 3/4 
neutropenia was similar for 
both groups; however, a higher 
percentage of patients in the 
vatalanib group experienced 
grade 3/4 hypertension, diar-
rhea, fatigue, nausea, vomiting, 
dizziness, confused state, deep 
vein thrombosis, and pulmonary 
embolism
Semaxanib [42] Study conducted with the objec-
tive of determining the maximum 
tolerated dose and dose-limiting 
toxicities in combination with 
weekly irinotecan in patients with 
advanced CRC who had failed at 
least one prior treatment
NA There were no drug-related 
Grade 4 toxicities. There was one 
episode of Grade 3 headache and 
one episode of Grade 3 vomiting
Regorafenib [44] CORRECT 
trial
Patients with mCRC and progres-
sion during or within 3 mo after 
the last standard therapy were 
randomised to receive best sup-
portive care plus oral regorafenib 
160 mg or placebo once daily, for 
the first 3 wk of each 4 wk cycle
Median OS was 6.4 mo in the rego-
rafenib group vs 5.0 mo in the placebo 
group (HR = 0.77; 95%CI: 0.64-0.94; one-
sided P = 0.0052)
The grade 3 or higher of adverse 
effects related to regorafenib 
were hand-foot skin reaction (83 
patients, 17%), fatigue (48, 10%), 
diarrhoea (36, 7%), hypertension 
(36, 7%), and rash or desquama-
tion (29, 6%)
Brivanib [47] Siu et al[47] Patients previously treated were 
assigned 1:1 to receive cetuximab 
400 mg/m intravenous loading 
dose followed by weekly main-
tenance of 250 mg/m plus either 
brivanib 800 mg orally daily (arm 
A) or placebo (arm B)
Median OS in the intent-to-treat popula-
tion was 8.8 mo in arm A and 8.1 mo in 
arm B (HR = 0.88; 95%CI: 0.74-1.03; P = 
0.12). Median PFS was 5.0 mo in arm A 
and 3.4 mo in arm B (HR = 0.72; 95%CI: 
0.62-0.84; P < 0.001)
Grade ≥ 3 adverse events was 
78% in arm A and 53% in arm B
Cediranib [48] HORIZON 
Ⅲ
Patients randomly assigned 1:1:1 
received mFOLFOX6 with cedira-
nib or bevacizumab
 There are not significant differences in 
PFS (HR = 1.10; 95%CI: 0.97-1.25; P = 
0.119), OS (HR = 0.95; 95%CI: 0.82-1.10; 
P = 0.541) and overall response rate 
(46.3% vs 47.3%)
Cediranib arm adverse events 
included diarrhea, neutropenia, 
and hypertension
PFS: Progression free survival; OS: Overall survival; HR: Hazard ratio; 5-FU: 5-fluourouracil; LV: Leucovorin; FOLFIRI: 5-FU, LV and irinotecan; FOLFOX: 
5-FU, LV and oxaliplatin; mCRC: Metastatic colorectal cancer; NA: Not available.
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use of  cediranib or bevacizumab with respect to OS and 
PFS. Thus, this drug is not currently used in our clinical 
practice.
CONCLUSION
Nowadays, the new era of  molecular cancer profiling 
has emerged in order to help clinicians in their decision 
making. Taking this into account, many targeted drugs 
are objects of  extensive interest for the scientific commu-
nity. In colorectal cancer, only bevacizumab, cetuximab, 
regorafenib and panitumumab have acquired sufficient 
evidence to be used in combination with standard che-
motherapy to improve patient outcomes. However, the 
results are not strong enough for the national public 
systems to support their complete use in all countries. 
Pharmaco-economics studies are needed prior to ap-
prove those biological drugs towards the cancer care in-
stitutions. However, it is important for oncologists to be 
aware of  patients cost and benefit in order to provide the 
best care for mCRC patients.
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